Conformal High Dose Rate Brachytherapy Improves Biochemical Control And Cause Specific Survival in Patients With Prostate Cancer And Poor Prognostic Factors

• DOI: 10.1097/01.ju.0000052720.62999.a9
• Publication Date: 2003-11-18T22:40:09Z
• Authors: ALVARO MARTINEZ; JOSE GONZALEZ; WILLIAM SPENCER; GARY GUSTAFSON; LARRY KESTIN; DAVID KEARNEY; FRANK A. VICINI
• Keywords: Aged, 80 and over; Male; Brachytherapy; Prostatic Neoplasms; Radiotherapy Dosage; Adenocarcinoma; Middle Aged; Prostate-Specific Antigen; Iridium Radioisotopes; Prognosis; Disease-Free Survival; 3. Good health; Survival Rate; 03 medical and health sciences; 0302 clinical medicine; Actuarial Analysis; Multivariate Analysis; Humans; Prospective Studies; Radiotherapy, Conformal; Aged

To improve outcome for patients with prostate cancer with poor prognostic factors higher than conventional radiation doses are required. To achieve this outcome a brachytherapy boost was given. We report the results of the first high dose rate dose-escalation brachytherapy trial.Between 1991 and 2000, 207 patients were prospectively enrolled in a dose escalation trial including pelvic radiotherapy and conformal high dose rate prostate brachytherapy boost. The dose was increased from 5.5 to 11.5 Gy. per implant. Patient eligibility for the study included pretreatment prostate specific antigen 10 or greater, Gleason 7 or greater or clinical stage T2b or higher. No patient received hormonal therapy. The American Society for Therapeutic Radiology and Oncology consensus panel definition of biochemical failure was applied.Median patient age was 69 years. Mean followup was 4.7 years (range 0.6 to 10.4). The 5-year actuarial biochemical control rate was 74%. The 5-year biochemical control was 85% for 1 poor prognostic factor, 75% for 2 and 50% for all 3 (p = 0.001). On Cox regression multivariate analysis lower brachytherapy dose, and higher Gleason and nadir value were associated with biochemical failure. The 5-year actuarial overall survival was 92%, cause specific survival 98% and disease-free survival 68%. The 5-year actuarial rates of complications were 8% and 0% for grades 3 and 4 genitourinary, and 0.5% and 0.5% for grades 3 and 4 gastrointestinal, respectively. The 5-year actuarial impotence rate was 51%.For patients with poor prognostic factors external beam radiation therapy with conformal high dose rate brachytherapy boost improved biochemical control, resulting in a high cause specific survival rate with low toxicity. Another important advantage is that the patient is not radioactive after the high dose rate implant.